The stock of Achaogen Inc (NASDAQ:AKAO) is a huge mover today! About 695,801 shares traded hands or 127.70% up from the average. Achaogen Inc (NASDAQ:AKAO) has risen 56.73% since April 27, 2016 and is uptrending. It has outperformed by 51.50% the S&P500.
The move comes after 8 months positive chart setup for the $162.78M company. It was reported on Nov, 30 by Barchart.com. We have $5.79 PT which if reached, will make NASDAQ:AKAO worth $4.88 million more.
Analysts await Achaogen Inc (NASDAQ:AKAO) to report earnings on March, 21. They expect $-0.47 earnings per share, up 22.95% or $0.14 from last year’s $-0.61 per share. After $-0.41 actual earnings per share reported by Achaogen Inc for the previous quarter, Wall Street now forecasts 14.63% negative EPS growth.
Achaogen Inc (NASDAQ:AKAO) Ratings Coverage
Out of 4 analysts covering Achaogen (NASDAQ:AKAO), 3 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 75% are positive. Achaogen has been the topic of 5 analyst reports since March 16, 2016 according to StockzIntelligence Inc. The firm earned “Buy” rating on Wednesday, November 2 by Aegis Capital. Needham downgraded the shares of AKAO in a report on Wednesday, March 16 to “Hold” rating. Wedbush upgraded Achaogen Inc (NASDAQ:AKAO) on Tuesday, June 14 to “Outperform” rating. The stock has “Outperform” rating given by Cowen & Co on Monday, November 28. The company was downgraded on Thursday, March 31 by Cowen & Co.
According to Zacks Investment Research, “Achaogen, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of novel antibacterials to treat multi-drug resistant, or MDR, gram-negative infections. The Company is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR enterobacteriaceae, including carbapenem-resistant enterobacteriaceae. Achaogen, Inc. is headquartered in South San Francisco, California.”
Insitutional Activity: The institutional sentiment decreased to 1.07 in Q2 2016. Its down 0.15, from 1.22 in 2016Q1. The ratio dropped, as 8 funds sold all Achaogen Inc shares owned while 10 reduced positions. 10 funds bought stakes while 12 increased positions. They now own 13.87 million shares or 102.18% more from 6.86 million shares in 2016Q1.
Gabelli Funds Limited Liability Corporation reported 52,800 shares or 0% of all its holdings. Tfs Cap Lc reported 13,587 shares or 0.01% of all its holdings. The New York-based Baker Bros Ltd Partnership has invested 0% in Achaogen Inc (NASDAQ:AKAO). Sphera Funds Mngmt Ltd last reported 1.24% of its portfolio in the stock. Fmr Llc accumulated 2.62M shares or 0% of the stock. Millennium Mngmt Limited Liability holds 0% of its portfolio in Achaogen Inc (NASDAQ:AKAO) for 24,043 shares. Ballentine Partners Ltd Liability Co holds 0.01% or 19,823 shares in its portfolio. Renaissance Technologies Llc, a New York-based fund reported 170,100 shares. Dafna Mgmt Limited Liability Com has 314,341 shares for 0.94% of their US portfolio. Nea Management Limited Liability Corporation, a Maryland-based fund reported 4.72M shares. Polar Capital Llp has 0.01% invested in the company for 100,000 shares. Blackrock Inv Llc has 0% invested in the company for 2,468 shares. Cornerstone Cap Mngmt Hldg Lc last reported 2,500 shares in the company. The Texas-based Eagle Glob Lc has invested 0% in Achaogen Inc (NASDAQ:AKAO). Vanguard Group has invested 0% of its portfolio in Achaogen Inc (NASDAQ:AKAO).
Insider Transactions: Since September 27, 2016, the stock had 0 insider purchases, and 2 insider sales for $20,217 net activity. Shares for $15,620 were sold by Wise Blake on Tuesday, September 27. On Tuesday, September 27 the insider Sarpangal Zeryn sold $4,597.
AKAO Company Profile
Achaogen, Inc., incorporated on November 26, 2002, is a clinical-stage biopharmaceutical company. The Firm is engaged in the discovery, development and commercialization of antibacterials to treat multi-drug resistant (MDR) gram-negative infections. The Firm is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant enterobacteriaceae (CRE). Plazomicin is an aminoglycoside designed to overcome clinically relevant aminoglycoside resistance mechanisms. In addition, its research and development pipeline includes two programs that specifically target Pseudomonas aeruginosa or Acinetobacter baumannii infections, which include a program to discover and develop small molecule inhibitors of LpxC, which is an enzyme essential for the synthesis of the outer membrane of gram-negative bacteria, and a therapeutic antibody program. The Company’s development plan for plazomicin includes over two Phase III clinical trials.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.